Long-acting cabotegravir not necessarily cost-effective for PrEP
(HealthDay)—For men who have sex with men and transgender women (MSM/TGW) at very high risk for HIV (VHR), the benefits of long-acting injectable cabotegravir (CAB-LA) in terms of life expectancy do not necessarily justify ...
Feb 01, 2022
0
3